新药申请-话题@MedSci

#新药申请#

77篇内容 | 2473人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1744185, encodeId=7a341e4418521, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=摆脱每日服药，**每月一次双药HIV疗法递交新药申请, objectType=article, longId=165251, objectId=1bce165251f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bce165251f4, replyNumber=0, likeNumber=63, createdTime=2020-04-10, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bce165251f4, moduleTitle=摆脱每日服药，**每月一次双药HIV疗法递交新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bce165251f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744188, encodeId=6d041e4418839, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=帕金森病的新型辅助治疗：FDA接受了Opicapone的新药申请（NDA）, objectType=article, longId=175277, objectId=eca41e5277bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eca41e5277bd, replyNumber=0, likeNumber=78, createdTime=2020-05-20, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eca41e5277bd, moduleTitle=帕金森病的新型辅助治疗：FDA接受了Opicapone的新药申请（NDA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eca41e5277bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744187, encodeId=4c771e441879d, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=FDA批准了ABO-202基因疗法治疗CLN1的研究性新药申请, objectType=article, longId=166647, objectId=a9b216664e69, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9b216664e69, replyNumber=0, likeNumber=93, createdTime=2019-09-22, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9b216664e69, moduleTitle=FDA批准了ABO-202基因疗法治疗CLN1的研究性新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9b216664e69)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744183, encodeId=725c1e4418340, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=FDA批准Heron的补充新药申请以扩大CINVANTI的标签, objectType=article, longId=161339, objectId=bce91613398a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bce91613398a, replyNumber=0, likeNumber=75, createdTime=2019-06-22, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bce91613398a, moduleTitle=FDA批准Heron的补充新药申请以扩大CINVANTI的标签, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bce91613398a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744186, encodeId=3dbe1e441867f, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=透皮避孕贴片Twirla：已向FDA提交新药申请（NDA）, objectType=article, longId=166332, objectId=508f1663327d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=508f1663327d, replyNumber=0, likeNumber=75, createdTime=2020-02-05, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=508f1663327d, moduleTitle=透皮避孕贴片Twirla：已向FDA提交新药申请（NDA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=508f1663327d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744180, encodeId=44691e44180df, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请, objectType=article, longId=160893, objectId=8353160893a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8353160893a6, replyNumber=0, likeNumber=56, createdTime=2020-02-08, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8353160893a6, moduleTitle=美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8353160893a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744177, encodeId=27f11e44177bb, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=百济神州宣布中国药监局接受zanubrutinib用于治疗复发/难治性套细胞淋巴瘤的新药申请, objectType=article, longId=147531, objectId=c60e14e531c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c60e14e531c9, replyNumber=0, likeNumber=64, createdTime=2019-03-04, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c60e14e531c9, moduleTitle=百济神州宣布中国药监局接受zanubrutinib用于治疗复发/难治性套细胞淋巴瘤的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c60e14e531c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744178, encodeId=2dbe1e44178d0, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=强生就Erdafitinib向美国FDA提交了新药申请, objectType=article, longId=149159, objectId=e1751491599c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1751491599c, replyNumber=0, likeNumber=65, createdTime=2019-02-12, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1751491599c, moduleTitle=强生就Erdafitinib向美国FDA提交了新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1751491599c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744179, encodeId=dfd01e44179ac, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请, objectType=article, longId=156675, objectId=905a1566e5bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=905a1566e5bb, replyNumber=0, likeNumber=80, createdTime=2019-01-08, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=905a1566e5bb, moduleTitle=AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=905a1566e5bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744175, encodeId=a0b91e44175bc, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=2017年1类新药申请量或将突破200个, objectType=article, longId=124203, objectId=8dbc124203f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dbc124203f4, replyNumber=0, likeNumber=76, createdTime=2018-06-10, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dbc124203f4, moduleTitle=2017年1类新药申请量或将突破200个, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dbc124203f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744176, encodeId=a4561e4417697, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=FDA受理了用于MPS IIIA治疗的SOBI003的新药申请并授予其快速通道资格, objectType=article, longId=127969, objectId=645212e969a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=645212e969a2, replyNumber=0, likeNumber=67, createdTime=2018-05-17, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=645212e969a2, moduleTitle=FDA受理了用于MPS IIIA治疗的SOBI003的新药申请并授予其快速通道资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=645212e969a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744174, encodeId=8e7f1e44174e8, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=Camurus宣布FDA批准优先审核关于CAM2038丁丙诺啡注射液的新药申请, objectType=article, longId=113794, objectId=dc9f113e9421, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc9f113e9421, replyNumber=0, likeNumber=87, createdTime=2018-06-20, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc9f113e9421, moduleTitle=Camurus宣布FDA批准优先审核关于CAM2038丁丙诺啡注射液的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc9f113e9421)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744172, encodeId=b4cc1e44172f1, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=一大波重磅新药申请临床获CDE受理, objectType=article, longId=71030, objectId=d944e103041, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d944e103041, replyNumber=0, likeNumber=64, createdTime=2016-11-01, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d944e103041, moduleTitle=一大波重磅新药申请临床获CDE受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d944e103041)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744170, encodeId=d1a51e441700f, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=FDA受理安斯泰来新一代前列腺癌口服药物Xtandi补充新药申请, objectType=article, longId=64043, objectId=8f426404391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f426404391, replyNumber=0, likeNumber=73, createdTime=2016-10-28, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f426404391, moduleTitle=FDA受理安斯泰来新一代前列腺癌口服药物Xtandi补充新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f426404391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744171, encodeId=8d3e1e4417156, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=重磅！卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功，上半年向CFDA提交新药申请, objectType=article, longId=68953, objectId=268b6895329, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=268b6895329, replyNumber=0, likeNumber=87, createdTime=2016-11-16, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=268b6895329, moduleTitle=重磅！卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功，上半年向CFDA提交新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=268b6895329)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744173, encodeId=a5b81e4417379, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=乳腺癌新药3期临床疗效显著，已向FDA提交新药申请, objectType=article, longId=73682, objectId=6f29e36828d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f29e36828d, replyNumber=0, likeNumber=68, createdTime=2017-06-09, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f29e36828d, moduleTitle=乳腺癌新药3期临床疗效显著，已向FDA提交新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f29e36828d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744169, encodeId=20181e441690d, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=中源协和干细胞抗肝纤维化注射液新药申请未获准, objectType=article, longId=48350, objectId=211648350bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=211648350bb, replyNumber=0, likeNumber=75, createdTime=2015-06-24, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=211648350bb, moduleTitle=中源协和干细胞抗肝纤维化注射液新药申请未获准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=211648350bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744167, encodeId=2e391e441677d, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=FDA接受审查阿斯利康肿瘤学药物易瑞沙（Iressa）新药申请, objectType=article, longId=43567, objectId=de934356ee2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de934356ee2, replyNumber=0, likeNumber=70, createdTime=2015-09-09, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de934356ee2, moduleTitle=FDA接受审查阿斯利康肿瘤学药物易瑞沙（Iressa）新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de934356ee2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744166, encodeId=fcf81e4416682, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=默沙东向日本药监局提交Omarigliptin治疗2型糖尿病的新药申请, objectType=article, longId=43448, objectId=bd1843448a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd1843448a5, replyNumber=0, likeNumber=76, createdTime=2015-10-05, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd1843448a5, moduleTitle=默沙东向日本药监局提交Omarigliptin治疗2型糖尿病的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd1843448a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744168, encodeId=adfd1e4416857, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=FDA接受审查阿斯利康肿瘤学药物易瑞沙（Iressa）新药申请, objectType=article, longId=43577, objectId=7674435e7b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7674435e7b1, replyNumber=0, likeNumber=65, createdTime=2015-02-05, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7674435e7b1, moduleTitle=FDA接受审查阿斯利康肿瘤学药物易瑞沙（Iressa）新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7674435e7b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

新药申请

2020-05-29

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

摆脱每日服药，**每月一次双药HIV疗法递交新药申请

2020-04-10

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

帕金森病的新型辅助治疗：FDA接受了Opicapone的新药申请（NDA）

2020-05-20

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

FDA批准了ABO-202基因疗法治疗CLN1的研究性新药申请

2019-09-22

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

FDA批准Heron的补充新药申请以扩大CINVANTI的标签

2019-06-22

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

透皮避孕贴片Twirla：已向FDA提交新药申请（NDA）

2020-02-05

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请

2020-02-08

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

百济神州宣布中国药监局接受zanubrutinib用于治疗复发/难治性套细胞淋巴瘤的新药申请

2019-03-04

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

强生就Erdafitinib向美国FDA提交了新药申请

2019-02-12

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请

2019-01-08

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

2017年1类新药申请量或将突破200个

2018-06-10

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

FDA受理了用于MPS IIIA治疗的SOBI003的新药申请并授予其快速通道资格

2018-05-17

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

Camurus宣布FDA批准优先审核关于CAM2038丁丙诺啡注射液的新药申请

2018-06-20

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

一大波重磅新药申请临床获CDE受理

2016-11-01

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

FDA受理安斯泰来新一代前列腺癌口服药物Xtandi补充新药申请

2016-10-28

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

重磅！卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功，上半年向CFDA提交新药申请

2016-11-16

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

乳腺癌新药3期临床疗效显著，已向FDA提交新药申请

2017-06-09

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

中源协和干细胞抗肝纤维化注射液新药申请未获准

2015-06-24

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

FDA接受审查阿斯利康肿瘤学药物易瑞沙（Iressa）新药申请

2015-09-09

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

默沙东向日本药监局提交Omarigliptin治疗2型糖尿病的新药申请

2015-10-05

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

FDA接受审查阿斯利康肿瘤学药物易瑞沙（Iressa）新药申请

2015-02-05

科室
- - 订阅+
  - 更多科室
工具
服务